Last10K.com

Incyte Corp (INCY) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

Incyte Corp

CIK: 879169 Ticker: INCY

 

Exhibit 99.1 

 

 

 

FOR IMMEDIATE RELEASE

 

Incyte Reports 2020 First Quarter Financial Results
and Provides Updates on Key Clinical Programs

 

-Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi
® (ruxolitinib) revenues of $459 million in Q1
 2020 (+22% vs Q1 2019)

 

-PemazyreTM (pemigatinib) approved by FDA as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma

 

-Data from successful Phase 3 TRuE-AD program for ruxolitinib cream presented at Revolutionizing Atopic Dermatitis (RAD) conference; NDA on track for end 2020

 

-Ruxolitinib and baricitinib in clinical trials to treat patients suffering from COVID-19

 

Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT

 

WILMINGTON, Del. – May 5, 2020 – Incyte (Nasdaq: INCY) today reports 2020 first quarter financial results, and provides a status update on the Company’s development portfolio.

 

“Our strong first quarter results highlight continued revenue momentum, led by robust demand across all three indications for Jakafi® (ruxolitinib),” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “As we navigate this unprecedented and uncertain time, we have implemented numerous initiatives as we seek to ensure continuity of patient care. We are continuing to execute on our goals, and we were very pleased to announce the FDA approval of PemazyreTM (pemigatinib), the first of three potential product approvals that we expect to announce in 2020. The FDA review of the capmatinib NDA and tafasitamab BLA are proceeding as expected and, following positive results from our Phase 3 TRuE-AD development program in atopic dermatitis, we are also on track to submit the NDA for ruxolitinib cream at the end of 2020, all of which positions us for what I expect to be a transformational year.”

 

COVID-19

 

Commercial, Supply and Clinical & Regulatory Impact

 


The following information was filed by Incyte Corp (INCY) on Tuesday, May 5, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Incyte Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Incyte Corp.

Continue

Assess how Incyte Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Incyte Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Legal
Other
Filter Subcategory:
All
Product
Shares
Expense
Geography
Cash Flow
Earnings
Income
Debt
Other
Inside Incyte Corp's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Cash Flows (Parenthetical)
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Stockholders' Equity
Condensed Consolidated Statements Of Stockholders' Equity (Parenthetical)
Accrued And Other Current Liabilities
Accrued And Other Current Liabilities (Details)
Accrued And Other Current Liabilities (Tables)
Concentration Of Credit Risk And Current Expected Credit Losses
Concentration Of Credit Risk And Current Expected Credit Losses (Details)
Concentration Of Credit Risk And Current Expected Credit Losses (Tables)
Contingencies
Debt
Debt (Tables)
Debt - Carrying Amount And Fair Value (Details)
Debt - Components Of Convertible Notes (Details)
Debt - Narrative (Details)
Employee Benefit Plans
Employee Benefit Plans (Tables)
Employee Benefit Plans - Defined Contribution Plan (Details)
Employee Benefit Plans - Periodic Benefit Cost (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Fair Value On A Recurring Basis (Details)
Fair Value Of Financial Instruments - Marketable Securities Portfolio (Details)
Income Taxes
Income Taxes (Details)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Details)
Intangible Assets And Goodwill (Tables)
Inventory
Inventory (Details)
Inventory (Tables)
License Agreements
License Agreements - Agenus (Details)
License Agreements - Calithera (Details)
License Agreements - Innovent (Details)
License Agreements - Lilly (Details)
License Agreements - Macrogenics (Details)
License Agreements - Merus (Details)
License Agreements - Morphosys (Details)
License Agreements - Novartis (Details)
License Agreements - Syros (Details)
License Agreements - Zai Lab (Details)
Net Income (Loss) Per Share
Net Income (Loss) Per Share (Details)
Net Income (Loss) Per Share (Tables)
Organization And Business
Organization And Business (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Buildings And Construction (Details)
Property And Equipment, Net - Lease And Maturity Of Lease Liabilities (Details)
Property And Equipment, Net - Property And Equipment, Net (Details)
Revenues
Revenues (Details)
Revenues (Tables)
Stock Compensation
Stock Compensation (Details)
Stock Compensation (Tables)
Stock Compensation - Option Activity (Details)
Stock Compensation - Rsu And Psu (Details)
Stock Compensation - Rsu And Psu Award Activity (Details)
Stock Compensation - Shares Available For Grant (Details)
Subsequent Event
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)
Summary Of Significant Accounting Policies - Revenue Recognition (Details)
Ticker: INCY
CIK: 879169
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-20-005185
Submitted to the SEC: Tue May 05 2020 4:09:15 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, March 31, 2020
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/incy/0001558370-20-005185.htm